Showing results (1-10 of 18) with videos related to
Sort By:
Pageof 2
Journal of Experimental Therapeutics & Oncology|November 11, 2011
CD22 as a target for cancer therapyXiao Tu, Theresa LaVallee, Robert LechleiderImmunotherapy|June 29, 2016
Targeting KIT on innate immune cells to enhance the antitumor activity of checkpoint inhibitorsMaximilian Stahl, Richard Gedrich, Ronald Peck, et al.Journal for Immunotherapy of Cancer|July 24, 2023
Society for Immunotherapy of Cancer (SITC) checkpoint inhibitor resistance definitions: efforts to harmonize terminology and accelerate immuno-oncology drug developmentHarriet M Kluger, Hussein Tawbi, David Feltquate, et al.Journal of Translational Medicine|July 28, 2025
Germline microRNA-based signatures predict toxicity and response to anti-CTLA-4 therapyJoanne B Weidhaas, Kristen M McGreevy, Nicholas Marco, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 17, 2019
Molecular and Clinical Activity of CDX-3379, an Anti-ErbB3 Monoclonal Antibody, in Head and Neck Squamous Cell Carcinoma PatientsUmamaheswar Duvvuri, Jonathan George, Seungwon Kim, et al.Journal for Immunotherapy of Cancer|March 14, 2023
Society for Immunotherapy of Cancer (SITC) consensus definitions for resistance to combinations of immune checkpoint inhibitorsHarriet Kluger, J Carl Barrett, Justin F Gainor, et al.Journal of Translational Medicine|April 22, 2022
The "Great Debate" at Immunotherapy Bridge 2021, December 1st-2nd, 2021Paolo A Ascierto, Lisa H Butterfield, Olivera J Finn, et al.Scientific Reports|June 26, 2019
HER3 targeting potentiates growth suppressive effects of the PI3K inhibitor BYL719 in pre-clinical models of head and neck squamous cell carcinomaKara S Meister, Neal R Godse, Nayel I Khan, et al.Journal of Pharmaceutical Sciences|October 24, 2012
Pharmacokinetic and pharmacodynamic comparability study of moxetumomab pasudotox, an immunotoxin targeting CD22, in cynomolgus monkeysBing Wang, Meina Liang, Zhenling Yao, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 16, 2014
Phase I dose-escalation study of MEDI-573, a bispecific, antiligand monoclonal antibody against IGFI and IGFII, in patients with advanced solid tumorsPaul Haluska, Michael Menefee, Elizabeth R Plimack, et al.Pageof 2